On Sep 23, 2016, the editorial team of Hepatoma Research (Hepatoma Res, HR) visited Prof. Shu-Kui Qin, Chairman of the Chinese Society of Clinical Oncology (CSCO) and member of the American Society of Clinical Oncology (ASCO) in Xiamen, China. The team introduced HR to Prof. Shu-Kui Qin with the mission and vision of HR: "Focusing on being the most influential academic journal with open-access in the field of liver cancer, and contributing to liver cancer research and therapeutic innovation". The team also presented recent HR progresses, such as editorial board, quantity of publications and associated citations and downloading, and global distribution of authors and readers. The team extended sincere invitation to Prof. Shu-Kui Qin to join the HR editorial board. Prof. Shu-Kui Qin listened to HR presentation, read the latest August issue of HR, and praised the achievements of HR over the past and half years since its establishment in April 2015. Prof. Shu-Kui Qin confirmed that the articles published in HR covers all fields of hepatoma and provides a platform of communication for academic researchers and clinicians. Prof. Shu-Kui Qin particularly commented on three articles as "high-quality publications" (1. Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies; 2. Percutaneous hepatic perfusion with melphalan for unresectable liver metastasis; 3. Hepatitis B virus molecular biology and pathogenesis) recently published in HR.
At the end of the meeting, Prof. Shu-Kui Qin pleasantly accepted the invitation to join HR as the Honorary Editor-in-chief. For future HR development, Prof. Shu-Kui Qin suggests that HR to focus on international liver cancer research, especially in Asian-Pacific region, follow up with the hotspots in the field of liver cancer research, carry out rigorous peer-review, and provide authors and readers with top-quality service. Prof. Shu-Kui Qin also encouraged the HR editorial team to insist on publishing high-quality research articles and being the excellent, free open-access platform and the first-class international academic journal.
Prof. Shu-Kui Qin, Chair of Chinese Society of Clinical Oncology (CSCO), is the Deputy Director of People's Liberation Army (PLA) 81 Hospital (Nanjing, China), Director of Cancer Center of Chinese PLA, and Director of National Drug Clinical Trial Agency of PLA 81 Hospital. He serves as the Executive Member of the Asian Clinical Oncology Society (ACOS), Council Member of PLA Medical Science Commission (and the Executive Member of its oncology society), Member of the Oncology Branch of Chinese Medical Association, Expert Committee Member of National Tumor Standardized Diagnosis and Treatment of Ministry of Health (and also the leader of the Liver Cancer Expert Panel and Cancer Pain Expert Panel), Vice President of Beijing Xisike Clinical Oncology Research Foundation, and Member of Chinese Anti-cancer Association (CACA) (and the Vice Chairman of the Committee of Rehabilitation and Palliative Care affiliated to CACA). After decades of clinical practice and scientific research, Prof. Shu-Kui Qin has accumulated rich experiences in the medical treatment of gastrointestinal cancers and their bone metastases. Prof. Shu-Kui Qin has published over 400 articles in peer-reviewed journals and 44 scientific books. He has been granted numbers of professional awards at the ministerial and provincial levels (including four first-class prizes, two second-class prizes,seven third-class prizes, and two fourth-class prizes). He enjoys special allowance from State Council of China and the PLA.